Results

Total Results: 1,430 records

Showing results for "continued".

121. Diabetes-Foot-Ulcer-Amputation-Prevalence Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-foot-ulcer-amputation-prevalence_research.pdf
     February 01, 2011 - Prevalence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006 to 2008 Diabetic Foot Ulcers Data Points #1 The prevalence of diabetes in the Medicare population may be one-third higher than previously estimated. Overall, approximately 8% of diabetic Medicare ben…

122. Slide 1 (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/module_i1.ppt
     May 29, 2025 - stakeholders as a central element of the EHC Program since its inception, and has clearly outlined the continued … Stakeholder input maximize usefulness of EHC Program products AHRQ’s vision for stakeholder engagement has continued

123. Attention Deficit Hyperactivity Disorder: Executive Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/adhd_executive.pdf
     October 01, 2011 - Following medication titration and the RCT phase, approximately 46 percent continued in the 10­month … Two reports focus on the safety and continued efficacy of the noradrenergic agonist GXR.70,71 Three … Global ratings of impairment also indicate continued benefit throughout the extension studies for patients … In general, those who remain on medication show continued benefit, and few adverse events are reported … All other domains show skill maintenance but not continued growth.

124. Liver-Cancer-Therapy Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_executive.pdf
     May 01, 2013 - PICOTS for the Key Questions (continued) PICOTS KQ1 KQ2 KQ3 Outcome • Final health outcomes: Survival … Summary GRADE strength of evidence for KQ1 and KQ2 (continued) Key Question, Comparison, and Outcome … Summary GRADE strength of evidence for KQ1 and KQ2 (continued) Key Question, Comparison, and Outcome … Summary GRADE strength of evidence for KQ1 and KQ2 (continued) Key Question, Comparison, and Outcome … Summary GRADE strength of evidence for KQ1 and KQ2 (continued) Key Question, Comparison, and Outcome

125. Stroke-Atrial-Fibrillation Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/stroke-atrial-fibrillation_executive.pdf
     August 01, 2013 - strength of evidence and effect estimates for KQ 3 (interventions for preventing thromboembolic events) (continued … strength of evidence and effect estimates for KQ 3 (interventions for preventing thromboembolic events) (continued … strength of evidence and effect estimates for KQ 3 (interventions for preventing thromboembolic events) (continued … strength of evidence and effect estimates for KQ 3 (interventions for preventing thromboembolic events) (continued … Given the number of treatment strategies available, initial research might be focused on comparing continued

126. Disposition of Comments: CER 228, Nonopioid Pharmacologic Treatments for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-228-nonopioid-pharm-chronic-pain-comments.pdf
     April 16, 2020 - Public Reviewer 4 Jacob Marzalik, American Psychological Association Question 2 We appreciate the continued … We agree that continued research on this topic is needed and important.

127. Back (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/back.pdf
     January 01, 2011 - Back Slide  1: Decision making  when clinical evidence  is limited: Palliative  chemotherapy  for cancer Anthony Back, MD University of Washington Fred  Hutchinson Cancer Research Center Seattle, Washington Slide  2: The  problem • 33 yo  man …

128. Slide 1 (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/module_iv1.ppt
     May 29, 2025 - Incorporate suggestions The level of and opportunities for stakeholder involvement in the EHC Program have continued

129. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1512.pdf
     December 29, 2015 - Treatment benefit continued at 52 and 104 week followup in some patients. … Treatment benefit continued up to 52 or 104 weeks in some patients. … Treatment benefit continued through 24 weeks for baricitinib 4 mg. … Treatment benefit continued through 24 weeks for baricitinib 4 mg. … Treatment benefit continued through 24 weeks for baricitinib 4 mg.

130. Wheeled Mobility (Wheelchair) Service Delivery (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/wheelchair-service_technical-brief.pdf
     January 01, 2012 - Models and descriptions of wheeled mobility service delivery (continued) B. … Studies of wheeled mobility service delivery (continued) Reference Study Purpose Population Included … Studies of wheeled mobility service delivery (continued) Reference Study Purpose Population Included … Studies of wheeled mobility service delivery (continued) Reference Study Purpose Population Included … Studies of wheeled mobility service delivery (continued) Reference Study Purpose Population Included

131. Cer-238-Cervical-Ripening-Appendix-E-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-238-cervical-ripening-appendix-e-1.xlsx
     January 01, 2009 - Patients randomized to intervention 1 had electronic FHR and uterine monitoring continued for at least … after Dilapan inserted, monitoring for contractions and fetal heart rate was continued

132. Pneumonia-Antibiotic-Treatment Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pneumonia-antibiotic-treatment_executive.pdf
     November 01, 2014 - Strength of evidence for comparisons of continuous and intermittent infusion (continued) 11 sepsis

133. Stem-Cell-Children Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/stem-cell-children_executive.pdf
     February 01, 2012 - Pediatric HSCT indications to be addressed with narrative review (continued) Type Disease Indication … Pediatric HSCT indications to be addressed with narrative review (continued) Type Disease Indication … Pediatric HSCT indications to be addressed with systematic review (continued) Type Disease Indication

134. BLUEPRINT FOR A FUTURE DISTRIBUTED RESEARCH NETWORK (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/distributed-network-blueprint_research.pdf
     June 01, 2010 - to be conducted in parallel with the development of the network, which will in turn help to inform continued … Data Sources and Types (Phase 2) Continued development should incorporate data from additional data … to be conducted in parallel with the development of the network, which will in turn help to inform continued

135. women-hiv-protocol-160301 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/women-hiv_research-protocol.pdf
     March 01, 2016 - impact of resources), older women who live with HIV may engage with resources, transiently, or in a continued … Alternatively, assess modifiers of initial or continued engagement with a resource (as defined by the … Eligible are cohort, case-control or cross-sectional studies assessing the association between initial or continued

136. Quantitative Synthesis: Chapter 2. Presenting Different Effects for Different Data Types (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-quantitative-synthesis-chapter-2.pdf
     February 01, 2018 - Quantitative Synthesis: Chapter 2. Presenting Different Effects for Different Data Types Quantitative Synthesis Chapter 2. Presenting Different Effects for Different Data Types Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews Methods Guide www.ahrq.gov …

137. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update--Executive Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/antipsychotics-children-update_executive.pdf
     January 01, 2018 - placebo Intermediate Outcomes (continued) Response (10, 1664) (Manic/mixed phases)d RR, 1.97; … placebo Intermediate Outcomes (continued) Remission (2, 311) 1 RCT: RR, 7.09; 95% CI, 2.96 to 16.99 … Risperidone Short-term (continued) ≥ 7% increase in weight 6 (504) 107 150 188 354 RR, 1.36; 95% … for general adverse effects: Short- and long-term findings of comparisons between different SGAs (continued … Continued guidance related to ongoing benefit-harm assessments for individual patients, regardless

138. Cancer-Drugs-Utilization Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-drugs-utilization_research.pdf
     January 01, 2011 - Utilization of anticancer biologic products among Medicare beneficiaries, by diagnostic cancer subchapter, 2006-2009 Anticancer Biologics Data Points #7 Fewer than 50 percent of beneficiaries with bevacizumab orders had a cancer diagnosis in the prior 6 months. This was driven by the biologic’s off-label use …

139. Data-Points 1 Diabetic-Foot-Ulcers Data 02-2011 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/data-points_1_diabetic-foot-ulcers_data_02-2011.xlsx
     January 01, 2011 - Prevalence of Diabetes Prevalence of Diabetes in Medicare Parts A and B Fee-for-Service (FFS) Cohort Population (Millions), 2007 Algorithm Period of continuous enrollment (months) Number of Beneficiaries in Enrollment Population Number of Beneficiaries with Diabetes Diabetes Rate in Enrolled Population 1 1 34.6 9…

140. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/plasma-cell-dyscrasias-sflc-assay-future_research.pdf
     September 01, 2012 - Nominated topics for future research needs for the SFLC assay in PCDs, according to rank* (continued … Nominated topics for future research needs for the SFLC assay in PCDs, according to rank* (continued … Nominated topics for future research needs for the SFLC assay in PCDs, according to rank* (continued … Nominated topics for future research needs for the SFLC assay in PCDs, according to rank* (continued … Nominated topics for future research needs for the SFLC assay in PCDs, according to rank* (continued